|
Market Closed -
Nasdaq
00:00:00 03/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 24.50 USD | +0.45% |
|
+0.95% | -11.62% |
| 09-09 | Beam Therapeutics Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 01:00 PM | |
| 09-08 | Shares of Beam Therapeutics Retreat After Updated Trial Data Disappoints | DJ |
Company Valuation: Beam Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 5,327 | 2,692 | 2,159 | 1,974 | 2,736 | 2,448 | - | - |
| Change | - | -49.47% | -19.78% | -8.58% | 38.6% | -10.51% | - | - |
| Enterprise Value (EV) 1 | 4,367 | 1,613 | 969.4 | 1,974 | 2,441 | 1,532 | 1,227 | 1,602 |
| Change | - | -63.05% | -39.92% | 103.62% | 23.66% | -37.24% | -19.93% | 30.6% |
| P/E | -13.8x | -9.47x | -15.8x | -5.41x | -34.2x | -5.55x | -5.13x | -5.53x |
| PBR | 6.19x | 3.66x | 2.14x | 2.83x | 2.28x | 2.92x | 2.6x | 3.84x |
| PEG | - | 0.3x | 0.3x | -0x | 0.4x | -0x | -0.64x | 0.76x |
| Capitalization / Revenue | 103x | 44.2x | 5.72x | 31.1x | 19.6x | 50.4x | 39x | 19.9x |
| EV / Revenue | 84.2x | 26.5x | 2.57x | 31.1x | 17.5x | 31.5x | 19.5x | 13x |
| EV / EBITDA | -11.3x | -4.97x | -6.2x | -5.01x | -6.75x | -3.26x | -2.29x | -3.12x |
| EV / EBIT | -11.1x | -4.77x | -5.49x | -4.75x | -6.36x | -3.1x | -2.2x | -2.81x |
| EV / FCF | -38.6x | -61.1x | -5.3x | -5.54x | -6.78x | -10.1x | -6.78x | -8.64x |
| FCF Yield | -2.59% | -1.64% | -18.9% | -18% | -14.8% | -9.9% | -14.7% | -11.6% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -5.77 | -4.13 | -1.72 | -4.58 | -0.81 | -4.418 | -4.774 | -4.428 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 51.84 | 60.92 | 377.7 | 63.52 | 139.7 | 48.57 | 62.75 | 123.3 |
| EBITDA 1 | -385 | -324.3 | -156.5 | -393.6 | -361.4 | -470.2 | -536.4 | -513.8 |
| EBIT 1 | -392.5 | -338.5 | -176.5 | -415.6 | -383.7 | -493.7 | -557.8 | -569.9 |
| Net income 1 | -370.6 | -289.1 | -132.5 | -376.7 | -79.99 | -461.8 | -536.6 | -537.8 |
| Net Debt 1 | -960.4 | -1,078 | -1,190 | - | -294.9 | -916.4 | -1,222 | -846.2 |
| Reference price 2 | 79.69 | 39.11 | 27.22 | 24.80 | 27.72 | 24.50 | 24.50 | 24.50 |
| Nbr of stocks (in thousands) | 66,849 | 68,821 | 79,326 | 79,592 | 98,693 | 99,926 | - | - |
| Announcement Date | 28/02/22 | 28/02/23 | 27/02/24 | 25/02/25 | 24/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -5.55x | 31.54x | -3.26x | -.--% | 2.45B | |
| 21.73x | 7.71x | 15.48x | 1.37% | 74.16B | |
| 29.82x | 8.57x | 26.7x | 0.04% | 57.39B | |
| 32.98x | 5.93x | 17.77x | 0.98% | 47.64B | |
| -21.31x | 230.81x | -22.97x | -.--% | 44.29B | |
| 33.26x | 3.23x | 13.97x | -.--% | 42.5B | |
| 46.77x | 5.41x | 29.66x | -.--% | 40.71B | |
| 27.63x | 7.93x | 20.48x | 0.41% | 30.97B | |
| 32.99x | 7.05x | 18.3x | -.--% | 28.53B | |
| -15.1x | 5.68x | -7.14x | -.--% | 24.34B | |
| Average | 18.32x | 31.38x | 10.90x | 0.28% | 39.3B | |
| Weighted average by Cap. | 22.10x | 32.03x | 13.45x | 0.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- BEAM Stock
- Valuation Beam Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
